- If you are wondering whether Solventum's current share price still reflects its underlying worth, you are not alone. Many investors are asking the same question as they reassess what counts as good value in healthcare.
- Over the past month, Solventum's share price moved from recent levels to close at US$62.76, with a 7 day return of a 4.6% decline and a 30 day return of a 16.4% decline that adds to a 20.6% decline year to date and a 16.0% decline over the last year.
- These moves have come as the market continues to digest broader sector sentiment and company specific developments that shape how investors view future cash flows and risk. For a stock with this return profile, it is especially important to separate short term price swings from longer term estimates of fair value.
- Solventum currently records a valuation score of 5 out of 6. The sections that follow will compare what different valuation methods imply about the shares, before finishing with a look at a more complete way to think about valuation beyond any single model.
Find out why Solventum's -16.0% return over the last year is lagging behind its peers.
Approach 1: Solventum Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting them back to today, so you can compare that value to the current share price.
For Solventum, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is reported at $16.52m. Analyst and extrapolated estimates see Free Cash Flow figures such as $358.25m in 2026 and around $1,057.06m by 2035, with the nearer term years informed by analyst inputs and the later years extrapolated by Simply Wall St.
When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $83.77 per share. Compared with the recent share price of $62.76, this implies an intrinsic discount of roughly 25.1%. This indicates that the shares are currently priced below this DCF estimate of value.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Solventum is undervalued by 25.1%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.
Approach 2: Solventum Price vs Earnings
For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It reflects what the market is currently willing to pay, while linking directly to the bottom line that ultimately matters to shareholders.
What counts as a “normal” or “fair” P/E depends on how the market views growth and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually lines up with a lower one.
Solventum currently trades on a P/E of 7x. This is well below the Medical Equipment industry average P/E of about 27.73x and the broader peer group average of 28.83x. Simply Wall St’s Fair Ratio for Solventum is 21.74x, which is a proprietary estimate of the P/E that might be expected given its earnings profile, industry, profit margins, market cap and risks.
The Fair Ratio can be more informative than a simple comparison with peers or the industry because it explicitly factors in company specific growth expectations, risk and profitability rather than assuming all companies deserve the same multiple. Compared with this 21.74x Fair Ratio, Solventum’s current 7x P/E suggests the shares trade at a discount on this metric.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Solventum Narrative
Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, giving you a simple way to connect your view of Solventum's story with concrete numbers such as your own fair value, revenue, earnings and margin assumptions. You can then compare that to the current price so you can judge whether the stock looks attractive or stretched.
On Simply Wall St's Community page, Narratives are available as an easy tool that lets you and other investors set out these assumptions in a structured forecast and link them directly to an implied fair value. You can then see instantly how that stacks up against the market price to inform potential investment decisions.
Because Narratives update automatically when new information like earnings results or news is added, your view does not stay static. You can also see how others adjust their forecasts. For example, some Solventum Narratives currently anchor around higher fair values near US$105.00, while more cautious Narratives sit closer to US$71.00, reflecting different expectations about future revenue, margins and earnings based on the same underlying company data.
Do you think there's more to the story for Solventum? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com